werewolf therapeutics

- Renaissance Capital Werewolf Therapeutics is a biopharmaceutical company developing therapeutics engineered to stimulate the body’s immune system. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Sie können Ihre Auswahl jederzeit ändern, indem Sie Ihre Datenschutzeinstellungen aufrufen. It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf Therapeutics, Inc. Common Stock (HOWL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Biotechnology startup Werewolf Therapeutics Inc. gathered $56 million in venture financing to seek solutions to problems that have hindered a promising type of cancer immunotherapy. The current TTM dividend payout for Werewolf Therapeutics (HOWL) as of May 21, 2021 is $0.00 . Research Associate, Immunology, Cambridge, Mass., April 29, 2021 – Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company. Investing in an IPO is a high-risk instrument. Our team of experienced scientists invented our proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. President, Chief Executive Officer and Board member, Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering, Werewolf Therapeutics Appoints Tim Trost as Chief Financial Officer, Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic. Press Releases. But evaluating the performance of companies like Werewolf Therapeutics can be useful in determining how the market is performing and whether now is a good time to invest in this industry. The … Veteran life sciences financial executive brings over 25 years finance and capital markets expertise Cambridge, Financing accelerates Werewolf’s pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development, The successful candidate will be a creative scientist, with strong problem-solving skills and demonstrated experience in protein biochemistry and antibody/therapeutic, The successful candidate will be an experienced research associate who will contribute to the design and execution of our experimental. Werewolf Therapeutics howls onto the Nasdaq with $120M IPO Werewolf’s shape-shifting drugs are designed to deliver the benefits of cytokines without their … The … Werewolf Therapeutics is backed by leading life science investors and led by an experienced team with a proven track record of developing novel medicines for the treatment of cancer. The Werewolf Therapeutics 52-week high stock price is 23.99 , which is 100.4% above the current share price. Werewolf Therapeutics is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body’s immune response to selectively target cancer. Werewolf Therapeutics is a biopharmaceutical company developing therapeutics engineered to stimulate the body’s immune system. Jefferies & Co. è positivo sul titolo e consiglia Buy. Werewolf Therapeutics, Inc. (Nasdaq: HOWL) visits the Nasdaq MarketSite in Times Square. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of … After banking $72 million at the start of the year, Werewolf Therapeutics now wants an IPO. Werewolf Therapeutics, Inc. is a biopharmaceutical company. Werewolf Therapeutics, Inc. is an oncology biotherapeutics company unleashing the power of proinflammatory immune modulators to develop next-generation, transformative cancer therapeutics. Payout Estimate. May. Past investment results do not guarantee future returns. Werewolf Therapeutics has filed to raise $100 million in an IPO, although the final figure may differ. This price target is based on 4 analysts offering 12 month price targets for Werewolf Therapeutics in the last 3 months. Immunotherapy represents one of the greatest advances for people living with cancer, but off-target effects remain a challenge in the clinical setting. Tue. Compare. A werewolf is a creature that can shape-shift, changing from its unassuming human form into a dangerous predator under specific conditions. Werewolf Therapeutics's main competitors include Curis, Boundless Bio, Ionova Life Science and Intrepida Bio. Werewolf Therapeutics Inc., which is developing cancer drugs using its Predator protein engineering technology, filed for an initial public offering. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to … As of 2021 May 19, Wednesday current price of HOWL stock is 12.010$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Werewolf Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. Werewolf Therapeutics has 24 employees at their 1 location and $56 m in total funding,. Global Indemnity Group … 18. The Company develops novel immuno-stimulatory therapeutics and medicines for the treatment of cancer diseases. RECENT FROM LINKEDIN. The average price target represents a 111.49% upside from the last price of $12.53. Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of … Select a company to learn more about what they do and how their stock performs, including market capitalization, the price-to-earnings (P/E) ratio , price/earnings-to-growth (PEG) ratio and dividend yield. Are you someone who makes things happen? Werewolf Therapeutics, Inc. is a biopharmaceutical company. Historical dividend payout and yield for Werewolf Therapeutics (HOWL) since 1971. Werewolf Therapeutics is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body’s immune response to … Werewolf Therapeutics, Inc. is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body's immune response to selectively target cancer. Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. Werewolf Therapeutics looks to make a killing in the public markets with a $100M IPO. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Do you want to work at a company that embraces the same ideals? Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of … See insights on Werewolf Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Click the link below and let us know that you’re interested. These therapies would boost the bodies ability to deal with cancer. Werewolf Therapeutics is developing medicines designed to be delivered systemically, but remain inactive in the body until they reach the tumor microenvironment, where they stimulate a powerful immune response and unleash an attack on cancer cells. Find the latest SEC Filings data for Werewolf Therapeutics, Inc. Common Stock (HOWL) at Nasdaq.com. Werewolf Therapeutics, Inc. 1030 Massachusetts Avenue, Suite 210 . We’d love to talk to you. Werewolf Therapeutics, Inc. operates as an oncology biotherapeutics company. Werewolf Therapeutics is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the … Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of … | 25 maggio 2021 Investing in an IPO is a high-risk instrument. Werewolf Therapeutics Biotechnology Cambridge, Massachusetts 2,369 followers Advancing a pipeline of next generation, transformative immuno-stimulatory medicines for cancer patients. Werewolf Therapeutics, Inc. (Nasdaq: HOWL) visits the Nasdaq MarketSite in Times Square. Global Indemnity, Werewolf Therapeutics See Activist Action. The average price target represents a 111.49% upside from the last price of $12.53. Events. Sie können 'Einstellungen verwalten' auswählen, um weitere Informationen zu erhalten und Ihre Auswahl zu verwalten. Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering . News & Research. We are advancing a novel class of cancer biotherapeutics designed to enhance the body’s immune response to cancer. Cambridge, MA 02138 (617) 952-0555 (Name, address, including zip code, and telephone number, including area code, of … Cambridge, Mass., April 29, 2021 – Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company Read More . Daten über Ihr Gerät und Ihre Internetverbindung, darunter Ihre IP-Adresse, Such- und Browsingaktivität bei Ihrer Nutzung der Websites und Apps von Verizon Media. Find the latest SEC Filings data for Werewolf Therapeutics, Inc. Common Stock (HOWL) at Nasdaq.com. The firm is developing candidates for solid tumors and other cancers. We were incorporated under the laws of the state of Delaware on October 19, 2017 under the name Werewolf Therapeutics, Inc. Our principal executive offices are located at 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138. Werewolf Therapeutics’ headquarters are located at 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138. These conditionally activated proinflammatory immune modulators, called INDUKINE™ molecules, are systemically administered in an inactive form and are selectively activated to deliver full biological potency of cytokines upon entering the tumor microenvironment. Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. OUR GOAL IS TO TRANSFORM THE LIVES OF CANCER PATIENTS. The current dividend yield for Werewolf Therapeutics as of May 21, 2021 is 0.00% . Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf is developing novel immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Werewolf Therapeutics Biotechnology Cambridge, Massachusetts 2,369 followers Advancing a pipeline of next generation, transformative immuno-stimulatory medicines for cancer patients. Past investment results do not guarantee future returns. Werewolf Therapeutics has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. For Werewolf Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Werewolf Therapeutics to generate income relative to … Veteran life sciences financial executive brings over 25 years finance and capital markets expertise CAMBRIDGE, Mass., Feb. 8, 2021 /PRNewswire/ -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to January 7, 2021 Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of … Research Associate/Sr. As it chases its shape-shifting cytokine drugs toward the clinic, Werewolf Therapeutics will collect $120 million in its Wall Street debut. We’re looking for vibrant, creative, forward-thinking people to join our team. (Note: Werewolf Therapeutics upsized its IPO at pricing on April 29, 2021, to 7.5 million shares, up from 6.25 million shares in the prospectus, at $16 – the mid-point of its $15-to-$17 range – to raise. Current and historical return on equity (ROE) values for Werewolf Therapeutics (HOWL) over the last 10 years. Werewolf Therapeutics, Inc. 1030 Massachusetts Avenue, Suite 210 . Current immunotherapy approaches target the minority of tumours that are visible to the immune system. By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer, increasing tumour visibility and extending the therapeutic benefit of immunotherapy to many more cancer patients. May 21, 2021 7:41 pm ET Order Reprints Print Article Activist Holdings . Explore commentary on Werewolf Therapeutics… It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The average price target is $26.50, with a high forecast of $32.00 and a low forecast of $22.00. May 21, 2021 7:41 pm ET Order Reprints Print Article Activist Holdings . Home Dividend Stocks Health Care Biotech Pharma Large Pharma Werewolf Therapeutics Inc (HOWL) Overview. The Company was founded in 2017. Grey Wolf Therapeutics awarded £1.1M to accelerate ERAP1 inhibitor programme in collaboration with University of Oxford and University of Southampton. Our combined expertise in oncology, immunology, and protein engineering is key for delivering effective cancer immunotherapies to the clinic and market to improve the lives of people who are living with cancer. The online platform IPO.LIMITED does not guarantee and does not promise future return on investment, does not guarantee the reliability of potential investments and the … As earnings news flow tapered, stocks took cues from clinical readouts. Compare Werewolf Therapeutics to its competitors by revenue, employee growth and … The Werewolf Therapeutics 52-week low stock price is 11.23 , which is 6.2% below the current share price. The company is … Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of … View detailed financial information, real-time news, videos, quotes and analysis on Werewolf Therapeutics, Inc. (NASDAQ:HOWL). This price target is based on 4 analysts offering 12 month price targets for Werewolf Therapeutics in the last 3 months. The company will use the funding to invest in research, talent acquisition, and advancement of its platform and therapeutic programs to early clinical development. Cambridge, MA 02138 (Name and Address of Agent for Service) (617) 952-0555 Weitere Informationen darüber, wie wir Ihre Daten nutzen, finden Sie in unserer Datenschutzerklärung und unserer Cookie-Richtlinie. The company is advancing a pipeline of treatments designed to focus the body’s immune response to selectively target cancer. … The company is … Cambridge, MA 02138 (Name and Address of Agent for Service) (617) 952-0555 Werewolf Therapeutics (HOWL) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the The Company develops novel immuno-stimulatory therapeutics and medicines for the treatment of … Trading Ideas. Our team brings together the unmatched determination and dedication of experienced physician-scientists and industry veterans with a proven track record in oncology drug development. The online platform IPO.LIMITED does not guarantee and does not promise future return on investment, does not guarantee the reliability of potential investments and the … Werewolf Therapeutics Inc., which is developing cancer drugs using its Predator protein engineering technology, filed for an initial public offering. Werewolf Therapeutics. When was Werewolf Therapeutics founded? Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. The average price target is $26.50, with a high forecast of $32.00 and a low forecast of $22.00. Werewolf Therapeutics, Inc. 1030 Massachusetts Avenue, Suite 210 . About the Werewolf Therapeutics Inc stock forecast. Werewolf Therapeutics, Inc. operates as an oncology biotherapeutics company. Werewolf Therapeutics Inc Dividend policy None Price as of: MAY 03, 12:00 PM EDT $16.26 +0.16 +0.99% Watchlist Overview. November 20, 2020. Werewolf Therapeutics, Inc. is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body’s immune response to selectively target cancer. Payout History. Werewolf Therapeutics, a biopharmaceutical company focused on treating cancer, has raised $120 million for its IPO after pricing its 7.5 million shares at … Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of … Designing conditionally activated therapeutics that unleash a powerful attack on cancer cells Company led by experienced team with proven track record of developing novel medicines for the treatment of cancer CAMBRIDGE, Mass., Nov. 20, 2019 /PRNewswire/ -- Werewolf Therapeutics, an … New. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. In honor of the occasion, Daniel J. Global Indemnity, Werewolf Therapeutics See Activist Action. ABOUT THIS EVENT Werewolf Therapeutics, Inc. (Nasdaq: HOWL) visits the Nasdaq MarketSite in Times Square. Werewolf Therapeutics fundamental comparison: Revenue vs Return On Equity. Company Profile. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Klicken Sie hier, um weitere Informationen zu unseren Partnern zu erhalten. The all-time high Werewolf Therapeutics stock closing price was 16.26 on May 03, 2021 . All rights reserved. Werewolf Therapeutics is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the … Werewolf Therapeutics debt/equity for the three months ending December 31, 1969 was 0.00 . That is exactly what the medicines that we are developing do. A werewolf is a creature that goes unnoticed in day-to-day life but transforms into a dangerous predator under specific conditions. Current and historical debt to equity ratio values for Werewolf Therapeutics (HOWL) over the last 10 years. Everything you need to know about the Werewolf Therapeutics IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. The company name is a powerful analogy to our scientific approach. It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf Therapeutics, Inc. is a biopharmaceutical company. Werewolf Therapeutics General Information Description. Virtual Conferences in November 2020. Durch Klicken auf "Alle akzeptieren" stimmen Sie zu, dass Verizon Media und unsere Partner Informationen durch die Nutzung von Cookies und ähnlichen Technologien auf Ihrem Gerät speichern und/oder darauf zugreifen und Ihre personenbezogenen Daten verarbeiten, um personalisierte Werbung und Inhalte anzuzeigen, für die Messungen von Werbung und Inhalten, für Informationen zu Zielgruppen und zur Produktentwicklung.

Tower Hamlets Councillors, Hazardous Waste Drop-off, Accident On 1960 Today 2021, Allegheny County Housing Authority Waiting List, A-z Waste And Recycling Guide, Hawthorn Aquatic Centre Opening Hours, Homes For Rent In Johnstown, Women's Super League Records, Euclid, Ohio Crime Rate,